Novo Nordisk A/S $NVO Shares Sold by Atria Investments Inc

Atria Investments Inc cut its stake in Novo Nordisk A/S (NYSE:NVO) by 9.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 152,729 shares of the company’s stock after selling 15,610 shares during the quarter. Atria Investments Inc’s holdings in Novo Nordisk A/S were worth $7,771,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of NVO. Franklin Resources Inc. lifted its holdings in Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors lifted its holdings in Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners acquired a new position in Novo Nordisk A/S in the third quarter valued at approximately $310,199,000. Clear Street Group Inc. acquired a new position in Novo Nordisk A/S in the third quarter valued at approximately $56,378,000. Finally, Armistice Capital LLC acquired a new position in Novo Nordisk A/S in the third quarter valued at approximately $40,841,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported encouraging early data for its oral Wegovy program, with trial results highlighting meaningful weight-loss efficacy and better tolerability, reinforcing confidence in the company’s GLP-1 pipeline. Article Title
• Positive Sentiment: The company’s recent Q1 results beat estimates and it raised its 2026 outlook, suggesting the core business remains resilient despite a tougher competitive environment. Article Title
• Positive Sentiment: Investor commentary is increasingly focused on Novo Nordisk’s restructuring efforts, oral Ozempic/Wegovy launches, and telehealth partnerships, which are being viewed as potential growth drivers. Article Title
• Positive Sentiment: Hims & Hers noted a Novo Nordisk GLP-1 partnership as part of its weight-loss care expansion, underscoring broader commercial adoption of Novo’s obesity treatments. Article Title
• Neutral Sentiment: Several articles discussed Novo Nordisk’s valuation, long-term returns, and stock forecasts, but these were mostly commentary pieces rather than new fundamental developments. Article Title
• Neutral Sentiment: There was also a disclosure about gifted share transactions linked to CFO associates, which appears administrative rather than a major operating issue. Article Title
• Negative Sentiment: Market commentary continues to emphasize competitive pressure from Eli Lilly’s expanding GLP-1 portfolio, raising concerns about Novo Nordisk’s ability to defend its obesity market leadership. Article Title
• Negative Sentiment: One analyst-style piece explicitly argued against upgrading the stock, reflecting skepticism that the recent rebound has fully resolved the company’s longer-term challenges. Article Title

Novo Nordisk A/S Stock Down 2.4%

Shares of NYSE:NVO opened at $44.71 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average of $39.73 and a two-hundred day moving average of $46.69. The stock has a market cap of $199.63 billion, a P/E ratio of 10.50, a PEG ratio of 4.08 and a beta of 0.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, research analysts expect that Novo Nordisk A/S will post 3.47 earnings per share for the current year.

Analyst Ratings Changes

NVO has been the subject of a number of analyst reports. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Wolfe Research initiated coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.